JP7132907B2 - ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法 - Google Patents

ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法 Download PDF

Info

Publication number
JP7132907B2
JP7132907B2 JP2019510843A JP2019510843A JP7132907B2 JP 7132907 B2 JP7132907 B2 JP 7132907B2 JP 2019510843 A JP2019510843 A JP 2019510843A JP 2019510843 A JP2019510843 A JP 2019510843A JP 7132907 B2 JP7132907 B2 JP 7132907B2
Authority
JP
Japan
Prior art keywords
composition
pterostilbene
nicotinamide riboside
substituted
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019510843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524856A5 (enExample
JP2019524856A (ja
Inventor
マルコチュリ，エリック・アレグザンダー
アルミナナ，ダニエル・アントニオ
Original Assignee
エリジウム・ヘルス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エリジウム・ヘルス・インコーポレイテッド filed Critical エリジウム・ヘルス・インコーポレイテッド
Publication of JP2019524856A publication Critical patent/JP2019524856A/ja
Publication of JP2019524856A5 publication Critical patent/JP2019524856A5/ja
Application granted granted Critical
Publication of JP7132907B2 publication Critical patent/JP7132907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2019510843A 2016-08-22 2017-08-22 ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法 Active JP7132907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378053P 2016-08-22 2016-08-22
US62/378,053 2016-08-22
PCT/US2017/047979 WO2018039207A1 (en) 2016-08-22 2017-08-22 Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders

Publications (3)

Publication Number Publication Date
JP2019524856A JP2019524856A (ja) 2019-09-05
JP2019524856A5 JP2019524856A5 (enExample) 2020-10-01
JP7132907B2 true JP7132907B2 (ja) 2022-09-07

Family

ID=61246253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510843A Active JP7132907B2 (ja) 2016-08-22 2017-08-22 ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法

Country Status (12)

Country Link
US (2) US11260069B2 (enExample)
EP (1) EP3500267A4 (enExample)
JP (1) JP7132907B2 (enExample)
KR (1) KR20190046895A (enExample)
CN (2) CN109982706A (enExample)
AU (1) AU2017316614B2 (enExample)
BR (1) BR112019003579A2 (enExample)
CA (1) CA3034673A1 (enExample)
MX (1) MX2019002211A (enExample)
RU (1) RU2019108100A (enExample)
WO (1) WO2018039207A1 (enExample)
ZA (1) ZA201901536B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7132907B2 (ja) 2016-08-22 2022-09-07 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法
EP3624808A4 (en) * 2017-05-18 2021-03-03 Elysium Health, Inc. PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
CA3108015A1 (en) 2017-07-28 2019-01-31 Centers For Age Control, Inc. Compositions and methods for preventing and reversing aspects of aging
CN112955150A (zh) * 2018-10-19 2021-06-11 达萨玛治疗公司 与nad+或nad+前体组合的sarm1抑制剂
WO2020102326A1 (en) * 2018-11-13 2020-05-22 Elysium Health, Inc Methods for determining and increasing nad levels
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
JP7580380B2 (ja) * 2019-02-26 2024-11-11 ウニベルシタット デ バレンシア―エストゥディ ジェネラル 運動ニューロン疾患を処置するための方法及び組成物
CN110812365A (zh) * 2019-11-07 2020-02-21 明特奇点医疗科技（北京）有限公司 一种组合物及其制备方法与制剂
CN111838669B (zh) * 2020-08-07 2022-11-29 四川大学华西医院 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
EP4079311B1 (en) 2021-04-20 2025-10-01 Nuvamid SA Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
WO2022269064A1 (en) * 2021-06-24 2022-12-29 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
DK4284387T3 (da) * 2021-06-24 2024-09-02 Vestlandets Innovasjonsselskap As Vis Nad-forstærkelsesterapi til parkinsons sygdom
CN117615768A (zh) * 2021-06-24 2024-02-27 韦斯特兰德特斯创新股份公司 用于帕金森病的nad增效疗法
CN118176006A (zh) * 2021-10-27 2024-06-11 益力舒健康公司 治疗更年期综合征的方法
EP4727544A2 (en) 2023-06-14 2026-04-22 Chromadex Inc. Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
CN116807985A (zh) * 2023-06-20 2023-09-29 风火轮(上海)生物科技有限公司 一种烟酰胺核糖组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501343A (ja) 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
JP2014514361A (ja) 2011-05-11 2014-06-19 アメリカ合衆国 プテロスチルベンの抗不安効果
WO2015186068A1 (en) 2014-06-02 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Preparation and use of crystalline beta-d-nicotinamide riboside

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
US20090163580A1 (en) * 2007-12-24 2009-06-25 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
WO2010095926A1 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
EP2445488B1 (en) 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
EP2574339A1 (de) * 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
US20130149277A1 (en) 2011-12-13 2013-06-13 Cliffstar Llc Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
JP6509844B2 (ja) * 2013-10-30 2019-05-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
WO2016122832A1 (en) * 2015-01-30 2016-08-04 Natural Formulations Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries
WO2016149277A1 (en) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
JP7132907B2 (ja) 2016-08-22 2022-09-07 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501343A (ja) 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
JP2014514361A (ja) 2011-05-11 2014-06-19 アメリカ合衆国 プテロスチルベンの抗不安効果
WO2015186068A1 (en) 2014-06-02 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Preparation and use of crystalline beta-d-nicotinamide riboside

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neurobiology of Aging，2012年，Vol.33,No.9，pp.2062-2071

Also Published As

Publication number Publication date
AU2017316614A1 (en) 2019-03-21
EP3500267A4 (en) 2020-03-18
CN109982706A (zh) 2019-07-05
MX2019002211A (es) 2019-10-30
RU2019108100A3 (enExample) 2020-11-27
US20220143055A1 (en) 2022-05-12
BR112019003579A2 (pt) 2019-05-21
US11998561B2 (en) 2024-06-04
US11260069B2 (en) 2022-03-01
RU2019108100A (ru) 2020-09-22
US20190201426A1 (en) 2019-07-04
ZA201901536B (en) 2024-06-26
EP3500267A1 (en) 2019-06-26
JP2019524856A (ja) 2019-09-05
CN115645432A (zh) 2023-01-31
WO2018039207A1 (en) 2018-03-01
CA3034673A1 (en) 2018-03-01
AU2017316614B2 (en) 2023-06-15
KR20190046895A (ko) 2019-05-07

Similar Documents

Publication Publication Date Title
US11998561B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
AU2020286208B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
CA3105341C (en) Methods of normalizing amino acid metabolism
ES2925902T3 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral
BRPI0807735A2 (pt) Composição farmacêutica composta de trigonelina e 4-hidroxiisoleucina e o processo da mesma
JP6420797B2 (ja) 活動意欲向上剤
JP2017036271A5 (enExample)
JP2015508805A (ja) コカイン中毒者の処置におけるモダフィニルの使用
HK40052619A (en) Methods of normalizing amino acid metabolism
BR112017026642B1 (pt) Composições de ribosídeo de nicotinamida e pteroestilbeno e seus usos
HK1254169B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
HK1254169A1 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
BR112018005943B1 (pt) Formulações de aminoácidos de administração oral com liberação modificada
BR112017027839B1 (pt) Uso de inibidores de vmat2 para preparação de uma composição farmacêutica para tratar mania em um transtorno de humor em um indivíduo; e/ou tratar transtorno obsessivo-compulsivo (toc) refratário ao tratamento
EP4422644A1 (en) Methods for treatment of menopausal syndromes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220601

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220621

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220713

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220826

R150 Certificate of patent or registration of utility model

Ref document number: 7132907

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250